1. Academic Validation
  2. Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension

Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension

  • Br J Pharmacol. 2015 Jun;172(12):3159-76. doi: 10.1111/bph.13117.
R Hernanz 1 2 S Martínez-Revelles 2 3 R Palacios 1 2 A Martín 1 2 V Cachofeiro 4 A Aguado 2 3 L García-Redondo 2 3 M T Barrús 1 P R de Batista 1 A M Briones 2 3 M Salaices 2 3 M J Alonso 1
Affiliations

Affiliations

  • 1 Dept. of Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • 2 Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain.
  • 3 Dept. of Farmacología, Universidad Autónoma de Madrid, Madrid, Spain.
  • 4 Dept. of Fisiología, Universidad Complutense de Madrid, Madrid, Spain.
Abstract

Background and purpose: Toll-like Receptor 4 (TLR4) signalling contributes to inflammatory cardiovascular diseases, but its role in hypertension and the associated vascular damage is not known. We investigated whether TLR4 activation contributed to angiotensin II (AngII)-induced hypertension and the associated vascular structural, mechanical and functional alterations.

Experimental approach: AngII was infused (1.44 mg · kg(-1) · day(-1), s.c.) for 2 weeks in C57BL6 mice, treated with a neutralizing anti-TLR4 antibody or IgG (1 μg · day(-1); systolic BP (SBP) and aortic cytokine levels were measured. Structural, mechanical and contractile properties of aortic and mesenteric arterial segments were measured with myography and histology. RT-PCR and Western blotting were used to analyse these tissues and cultured vascular smooth muscle cells (VSMC) from hypertensive rats (SHR).

Key results: Aortic TLR4 mRNA levels were raised by AngII infusion. Anti-TLR4 antibody treatment of AngII-treated mice normalised: (i) increased SBP and TNF-α, IL-6 and CCL2 levels; (ii) vascular structural and mechanical changes; (iii) altered aortic phenylephrine- and ACh-induced responses; (iv) increased NOX-1 mRNA levels, superoxide anion production and NAD(P)H oxidase activity and effects of catalase, apocynin, ML-171 and Mito-TEMPO on vascular responses; and (v) reduced NO release and effects of L-NAME on phenylephrine-induced contraction. In VSMC, the MyD88 Inhibitor ST-2825 reduced AngII-induced NAD(P)H oxidase activity. The TLR4 Inhibitor CLI-095 reduced AngII-induced increased phospho-JNK1/2 and p65 NF-κB subunit nuclear protein expression.

Conclusions and implications: TLR4 up-regulation by AngII contributed to the inflammation, endothelial dysfunction, vascular remodelling and stiffness associated with hypertension by mechanisms involving oxidative stress. MyD88-dependent activation and JNK/NF-κB signalling pathways participated in these alterations.

Figures
Products